Andhra HC verdict on Sun Pharma-Ranbaxy merger plea tomorrow

Image
Press Trust of India Hyderabad
Last Updated : May 23 2014 | 5:29 PM IST
The Andhra Pradesh High Court will tomorrow decide on the petition filed by two investors requesting it to restrain the BSE and NSE from giving any clearance to the scheme of amalgamation or merger between Sun Pharma and Ranbaxy.
After hearing the arguments from the counsels of the petitioners, Ranbaxy, Sun Pharma and SEBI, Justice G Chandraiah said he will pronounce the verdict tomorrow.
The petitioners alleged that there was heavy trading of Ranbaxy stock before the merger with Sun Pharma was announced on April 6, and requested the court to direct the SEBI to investigate the insider trading of Ranbaxy shares and take appropriate action against Sun Pharma and Silver Street Developers.
The court had earlier issued interim orders to maintain status quo with regard to the merger.
During the arguments, Y Suryanarana counsel of SEBI informed the court that an investigation is currently going on into the allegations of insider trading allegations.
Counsel for SEBI also said that the bourses are yet to forward their opinion on the merger or amalgamation issue to the market regulator.
D Prakash Reddy, senior counsel who argued for Ranbaxy said insider trading allegations and merger process are two different issues and hence be dealt with separately and cannot be mixed.
B Adinarayana Rao, counsel for Sun Pharma said the SEBI will investigate allegations of insider trading with regard to the persons involved with that and either Ranbaxy or Sun Pharma as companies have nothing to do with insider trading.
Sun Pharma Counsel also informed the court that merger or amalgamation process involves lengthy processes. The High Courts of Gujarat and Punjab and Haryana will issue public notices when both the companies approach for court approval.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 23 2014 | 5:29 PM IST

Next Story